Project Grant R15AI199861
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $393K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stevens Point, WI, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $272,125 to the University of Wisconsin System, operating through University of Wisconsin–Madison, on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds exploratory research investigating the evolutionary origins and consequences of starship-mediated variation in fungi. Starships are a newly identified group of giant transposons hypothesized to reshape fungal evolution and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $213,811 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop chimeric antigen receptor-engineered neutrophils as a therapeutic for Aspergillus fumigatus infection. The award funds research to engineer induced pluripotent stem cell-derived neutrophils armed with anti-Aspergillus CARs to overcome the limited efficacy of conventional antifungal agents...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $146,920 on November 30, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the molecular mechanisms of bacterial multidrug efflux transporters and antimicrobial resistance. The funded research combines deep mutational scanning with in vivo and in vitro validation to characterize how the NorA efflux transporter exports structurally and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Wisconsin–Madison a $427,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2027. The award supports research and development activities focused on creating an innovative probiotic-based therapeutic delivery system. The project centers on developing plasmid-independent, carbohydrate-regulated...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin – Madison $791,200 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize novel heterocyclic inhibitors against Naegleria fowleri and validate their molecular targets. The award supports development of drug candidates to treat N. fowleri meningoencephalitis, a parasitic brain infection with greater than 97 percent mortality for which no FDA-approved...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $1,591,093 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the role of c-di-AMP (CDA) in Listeria monocytogenes pathogenesis. The research examines how CDA, an essential nucleotide second messenger for bacterial growth and infection, attenuates virulence in important pathogens. While CDA accumulation is widely reported to reduce...
- The National Institute of Allergy and Infectious Diseases awarded The Medical College of Wisconsin, Inc. $649,014 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the conformation and functional dynamics of class B penicillin-binding proteins in enterococcal antimicrobial resistance. The project addresses the genetic and biochemical basis for cephalosporin resistance in antibiotic-resistant enterococci, which are major causes of...
- The National Institute of Allergy and Infectious Diseases awarded Prokaryotics Incorporated $299,697 on September 19, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a mechanistically novel antifungal agent targeting cell wall β-1,3-D-glucan biosynthesis with broad-spectrum activity against pathogenic yeasts and molds, including echinocandin-resistant strains. The project runs through February 28, 2027, with performance in Union, New Jersey. Phase 1...
- The National Institute of Allergy and Infectious Diseases awarded The Medical College of Wisconsin, Inc. $609,348 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate PASTA kinase signaling and enterococcal cell wall stress response. The research addresses two major knowledge gaps: the mechanisms by which the PASTA kinase IREK is controlled in response to antibiotic-mediated cell wall stress, and the mechanisms IREK uses to select its...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin System (University of Wisconsin - Madison) $414,305 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the promiscuity and mechanism of PACE transporters in bacterial cells. The research addresses substrate specificity and transport mechanisms of PACE (Proteobacterial Antiseptic Efflux) family transporters, which were discovered approximately...